Lifescell Eye amniotic cytokine extract ( EACE )
EACE is a highly reliable, stable and safe Eye tissue reconstruction product .
EACE is derived from the bio-nutrient and chemotactic factors of placental allograft which shows strong resemblance to the human Eye tissue with regard to chemical composition, porosity . The pronounced viscosity of the EACE supports a fast uptake of patient comfort , thus improving applications. The unique manufacturing process based on biotechnology removes all organic and potentially antigenic components,making the material absolutely safe and free of discomfort. EACE is the leading material , as demonstrated by its clinical and scientific success.
EACE product as a Eye tissue reconstruction allograft is a effective compound of different part of placental allograft . it is extracted from placenta and enriched by biofactors of amniotic and chorionic membrane by the growth factors and cytokines and also viscose materials of embilical cord .
EACE is a safe, reliable substitute with controlled resorption properties and excellent handling characteristics.
EACE product as a biotechnologic compound is produced in applicable size as 3cc .
EACE Product Mechanism of action
Innovative lifescell Eye tissue regeneration has become the new standard for reconstruction healing and repair. The goal of Eye tissue regeneration is to reconstruct or repair and replace damaged or diseased Eye tissue with healthy Eye tissue that is fully functional by bioactive elements . Eye tissue reconstruction is primarily composed of cells , extracellular matrixes and chemotactic factors like as growth factors and cytokines .
Cells are the biological building blocks of Eye tissue. They maintain the function of the Eye tissue by synthesizing proteins or metabolizing waste. Single cells communicate with one another and respond to stimuli in their surrounding environments. Cells secrete and maintain extracellular matrix (ECM) which is the structural component of Eye tissues reconstruction .
Cells interact with each other and the ECM through direct contact as well as soluble signaling molecules, including cytokines, growth factors, hormones, steroids, enzymes, and other chemicals. These signals stimulate a chain reaction or cascade which alters cell behavior, both in the releasing cell itself, as well as other neighboring cells of a Eye tissue.
Mechanism of action for EACE is relevant to The anti inflammatory bio actives to control of inflammatory parameters and also as a infra structure for cell immigration for reconstruction and healing which suggests support for local stem cells and transient amplifying local cells and promotes cell differentiation while excluding inflammatory cells and their protease activities. The composition is reflected into the controlled resorption behavior of EACE, which results in an initial integration of the particles followed by a complete resorption. While the fast resorption of some factors continuously increases the porosity of the material promoting Eye tissue integration by allowing ingrowth of cells and blood vessels, the other component provides volume stability for an extended time period .
This action assists healing Eye tissue reconstruction, consist of different bioactive elements to make Eye tissue reconstruction in the body and including but not limited to following bioactive elements :
• Multiple bioactive factors: Stimulate growth, cell division, and accelerate the treatment and repair of various types of Eye tissue defects. EACE properties are :
* Extra Cellular Matrix (ECM) composed of proteoglycan, glycosaminoglycan, glycoprotein, collagen (I, III, IV, VI, VIII), fibronectin, laminin, and elastin, and forms scaffolding to cover the Eye tissue reconstruction .
• Simulation and repair of lost Eye tissues due to the ability to differentiate and transform the immigrated stem cells including the Eye tissue of the transplantation place.
• Full biocompatibility and lack of of immunologic reactions due to the antigenicity and immunogenicity of the EACE as well as DNA Diminished during the complex preparation and production process.
• Induction and accelerated cellular migration at the local stages due to extracellular matrix, and an appropriate substrate for healing.
• Lack of local and systemic poisoning due to the absence of toxic and EACEcinogenic substances .
• Reduce inflammation due to inhibiting pro-inflammatory cytokines and inhibiting the activity of local neutrophil chemokine, macrophages, and also inhibition of T cell and B cell proliferation and apoptosis.
• Reduce the risk of fibrosis .
• Prevent excessive Eye tissue growth by stopping abnormal vascular growth.
EACE product Directions & Aplications
Improvement of the corneal transplant survival rate and Corneal wound treatment
Dry eye treatment
Corneal ulceration treatment in LASIK & LASEK surgery
Eye epithelial & scleral wound treatment
Corneal pressure ulcer repair
Corneal burn repair
Eye keratitis treatment
Pterygium treatment after surgery
Steven johnson syndrome treatment
Treatment of chemical damage and conjunctiva Reconstruction
Treatment of the relative defects of stem cells in Limbus area
Lifescell products Technology & immunity in production
The production line of Lifescell product is based on innovative PLACENTAL ALLOGRAFT Eye tissue engineering regulated by biotechnology standards and protocols. After selecting the donor, firstly the medical history of the person is carefully assessed and screened with the priority of the diseases transmittable through the blood. All donor mothers are screened for chronic, infectious, neurological, autoimmune, malignant, and other environmental factors. According to the AATB standard, these tests are repeated for the patient after the Window Period (NAT tests).
HIV-1 & HIV-2 Antibody
HIV Type 1 (Nucleic Acid Test)
HTLV-1 & HTLV-2 Antibody
Hepatitis B Core Antibody
Hepatitis B Surface Antigen
Hepatitic C Antibody
Hepatitic C Virus (Nucleic Acid Test)
CMV Total Antibody
Syphilis (Serological Test)
Lifescell EACE product COA ( Certificate of Analysis)
Product Description: eye amniotic cytokine extract
Site of Manufacturing: lifescell
Date of Manufacturing: 1398.01.08
Release Date: 1396.01.23
Certificate of Analysis No.: QC/CAS96015 Expiration Date at room temperature 1400.01.08
Drug product batch No.: CAS96015
The certificate of analysis data ie accredited by quality control department of lifescell biotechnology site and production line is in accordance with GMP articles and FDA regulation for good Eye tissue practices ( 21 CFR 1270,71) also in accordance to ministry of health regulations.